Evidence map›Paper›PMID 42562607›Full record

ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2026

Real-World Outcomes of [

Clément Bailly, Lavinia Vija, François Somme, Vincent Massard, Philippe Barthélémy, Anne-Laure Giraudet, Yann Godbert, Aude Fléchon, Sylvie Girault, Sophie Abadie-Lacourtoisie and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Clément BaillyNuclear Medicine Department, Nantes University Hospital, Nantes, France; clement.bailly@chu-nantes.fr.
Lavinia VijaDepartment of Nuclear Medecine, Oncopole Claudius Regaud, Toulouse, France.
François SommeNuclear Medicine and Molecular Imaging, Institut Strauss, Strasbourg, France.
Vincent MassardMedical Oncology Department, Institut de Cancérologie de Lorraine, Vandoeuvre-lès-Nancy, France.
Philippe BarthélémyDepartment of Medical Oncology, University Hospital Strasbourg, Strasbourg, France.
Anne-Laure GiraudetLumen Nuclear Medicine Department, Centre Léon Bérard, Lyon, France.
Yann GodbertDepartment of Thyroid Oncology and Nuclear Medicine, Institut Bergonié, Bordeaux, France.
Aude FléchonDepartment of Medical Oncology, Urological Oncology Centre Léon Bérard, Lyon, France.
Sylvie GiraultDepartment of Nuclear Medicine, ICO Pays de la Loire, Angers, France.
Sophie Abadie-LacourtoisieICO Paul Papin, Angers, France.
Caroline VialaNantes University Hospital, Nantes, France.
Alix DouilletMedical Department, Novartis, Rueil-Malmaison, France.
Stephanie ChêneMedical Department, Novartis, Rueil-Malmaison, France.
Pierre OlivierDepartment of Nuclear Medicine, CHRU Nancy, Nancyclotep Imaging Platform, Nancy, France; and.
Guilhem RoubaudDepartment of Medical Oncology, Institut Bergonié, Bordeaux, France.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metastatic castration-resistant prostate cancer (mCRPC) remains challenging to treat, especially after failure of standard therapies, such as androgen receptor pathway inhibitors and taxane-based chemotherapy. Radiopharmaceutical therapy with [

Indexed as

DipeptidesHeterocyclic Compounds, 1-RingLutetiumProstatic Neoplasms, Castration-ResistantAgedAged, 80 and overFranceHumansMaleMiddle AgedNeoplasm MetastasisProstate-Specific AntigenRadioisotopesTreatment OutcomeDipeptidesHeterocyclic Compounds, 1-RingLutetiumLutetium-177Prostate-Specific AntigenPSMA-617Radioisotopes[177Lu]Lu-PSMA-617early-access programmCRPCreal-world evidence

Identifiers

PMID42562607
PMCPMC13635079

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.